Research Synthesis: Longevity Metabolism Effects

Research Synthesis: Longevity Metabolism Effects

Abstract

Evidence-honesty note: 23/25 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes longevity metabolism effects as an aging-related intervention across 25 accepted source papers and 1463 high-confidence extracted claims.

The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 18 adjacent clinical sources, and 1 mechanistic or model-system source, with 86 cross-study disagreements across the evidence base.

No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, longevity, immune and inflammation outcome classes, and negative signals cluster in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that longevity metabolism effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

Methods

Review type and protocol

This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-longevity_metabolism_effects-v06-DAILY-2026-06-05T20-38-20Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-05.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• longevity metabolism effects aging
• longevity metabolism effects older adults
• longevity metabolism effects randomized controlled trial
• longevity aging
• longevity older adults
• longevity randomized controlled trial
• metabolism aging
• metabolism older adults
• metabolism randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses longevity metabolism effects.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 201 records in the receipt-candidate union, 71 were classified as source candidates and 25 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	201
Classified source candidates	71
No extractable claims	37
None-only claim binding	11
Mixed partial-or-none claim-binding candidates	63
Partial-only claim-binding candidates	14
Strict high-confidence sources	5
Admitted final sources	25

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, dosing and pharmacokinetics, frailty, immune and inflammation, longevity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=13; claims=754	no extracted directional signal in 12/13 sources	10 indirect; 3 review	limited corpus depth in this outcome class
Longevity	n=4; claims=66	no extracted directional signal in 4/4 sources	3 indirect; 1 mechanistic	limited corpus depth in this outcome class
Cardiometabolic	n=2; claims=22	unclear signal in 1/2 sources	1 indirect; 1 review	limited corpus depth in this outcome class
Immune and Inflammation	n=2; claims=149	no extracted directional signal in 2/2 sources	2 review	limited corpus depth in this outcome class
Population / prevalence	n=1; claims=14	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Dosing and Pharmacokinetics	n=1; claims=426	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Frailty	n=1; claims=20	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Skeletal, Fracture, and Bone	n=1; claims=12	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Contextual Adjacent Evidence Outcomes

13 included sources were assigned to this outcome class. Directional coding: mixed=1, null=12. Directness coding: indirect=10, review=3.

Longevity Outcomes

4 included sources were assigned to this outcome class. Directional coding: null=4. Directness coding: indirect=3, mechanistic=1.

Cardiometabolic Outcomes

2 included sources were assigned to this outcome class. Directional coding: null=1, unclear=1. Directness coding: indirect=1, review=1.

Immune Inflammation Outcomes

2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: review=2.

Population / prevalence Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Dose / exposure Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Frailty Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Skeletal Fracture Bone Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

Several outcome domains are supported by a single study within the corpus, precluding any internal replication check. Iron-metabolism and frailty associations draw on one cross-sectional analysis of community-dwelling older adults (Ma 2024), lactate-infusion effects on cognition and AD biomarkers derive from one acute-infusion protocol (Kemna 2025), and medium-chain triglyceride effects on gait-related skeletal-muscle glucose uptake rely on one longitudinal PET/CT cohort (Mutoh 2025). Single-trial findings therefore carry an inherently higher risk of chance findings, measurement artifacts, or idiosyncratic population effects that the corpus cannot independently adjudicate.

The external validity of the synthesis is constrained by the demographic narrowness of the enrolled populations. Adults without cardiometabolic disease, younger populations, and under-represented racial or ethnic groups are largely absent. The WHO overweight threshold of 25 kg/m² (WHO 2000) and the ADA HbA1c target of 7% (ADA 2024) are relevant benchmarks, but their clinical application to populations not represented here remains speculative.

No study in the corpus measured both a mechanistic metabolic readout and a clinically meaningful hard endpoint within the same trial design. Similarly, Flensted-Jensen 2025 (P < 0.0001 for multiple metabolic outcomes after 12 weeks of resistance training with polyphenol supplementation) and CarrilloArango 2025 (P < 0.0001 for acute energy-metabolism responses to velocity-based resistance training) report acute or short-duration metabolic improvements without linking them to incident disease or mortality. This mechanism-to-clinic gap — abundant metabolic signal, sparse outcome data — means that the synthesis can describe plausible biological pathways but cannot confirm that translating those pathways into clinical practice will yield net benefit on patient-relevant endpoints.

Conclusion

For longevity metabolism effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 25 included sources on Longevity Metabolism Effects across 8 outcome classes and 86 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 25 curated reference papers, the evidence base for Longevity Metabolism Effects shows a context-dependent profile. Null findings dominate: contextual other, longevity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Longevity Metabolism Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

Additional corpus sources included animal/preclinical evidence; the strongest unresolved contrast is the disagreement between Jung 2024 and Kurhaluk 2024 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Wei 2025) emphasize convergent signals on Longevity Metabolism Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
cardiometabolic	0	2	null, unclear	direct interventional hard-endpoint gap
longevity	0	4	null	direct interventional hard-endpoint gap
frailty	0	1	null	direct interventional hard-endpoint gap
contextual adjacent evidence	0	13	mixed, null	conflict-resolution gap
deficiency prevalence	0	1	null	direct interventional hard-endpoint gap
dosing and pharmacokinetics	0	1	null	direct interventional hard-endpoint gap
immune and inflammation	0	2	null	direct interventional hard-endpoint gap
skeletal, fracture, and bone	0	1	null	direct interventional hard-endpoint gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	cardiometabolic: direct interventional hard-endpoint gap	0 direct and 2 indirect sources; direction profile: null, unclear
P2	longevity: direct interventional hard-endpoint gap	0 direct and 4 indirect sources; direction profile: null
P3	frailty: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null
P4	contextual adjacent evidence: conflict-resolution gap	0 direct and 13 indirect sources; direction profile: mixed, null
P5	deficiency prevalence: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null

Next-Study Design Recommendation

The next high-yield study for Longevity Metabolism Effects should target the cardiometabolic evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Wei 2025; tier=B1; directness=review; endpoint=immune inflammation; direction=null; representative statistic=P < 0.00001.
• Flensted-Jensen 2025; tier=B2; directness=indirect; endpoint=dosing pharmacokinetics; direction=null; representative statistic=P = 0.0001.
• Sun 2025; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.0003.
• CarrilloArango 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.0001.
• Chen 2026; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null.
• Jung 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P < 0.001.
• Xiao 2025; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.001.
• Lei 2023; tier=B2; directness=indirect; endpoint=longevity; direction=null; representative statistic=P < 0.001.
• Kemna 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.001.
• Su 2022; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.01.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

Additional corpus sources included animal/preclinical evidence; - Severity 4 disagreement: Jung 2024 vs Kurhaluk 2024; Jung 2024 (mixed) vs Kurhaluk 2024 (null) on contextual other

• Severity 4 disagreement: Jung 2024 vs Wang 2025; Jung 2024 (mixed) vs Wang 2025 (null) on contextual other
• Severity 4 disagreement: Jung 2024 vs Xiao 2025; Jung 2024 (mixed) vs Xiao 2025 (null) on contextual other
• Severity 4 disagreement: Jung 2024 vs Chen 2025; Jung 2024 (mixed) vs Chen 2025 (null) on contextual other
• Severity 4 disagreement: Jung 2024 vs Wang 2025b; Jung 2024 (mixed) vs Wang 2025b (null) on contextual other
• Severity 4 disagreement: Jung 2024 vs Sun 2025; Jung 2024 (mixed) vs Sun 2025 (null) on contextual other
• Severity 4 disagreement: Jung 2024 vs Kemna 2025; Jung 2024 (mixed) vs Kemna 2025 (null) on contextual other
• Severity 4 disagreement: Jung 2024 vs CarrilloArango 2025; Jung 2024 (mixed) vs CarrilloArango 2025 (null) on contextual other

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Gong 2022, Lepine 2026, Ma 2022, Wang 2026, Liu 2022, Thota 2026, Vujovic 2026, Anisimov 2008, Ioannidis 2005.

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Morvaridzadeh 2024, Chen 2025b, Tancredi 2015.

References

• Flensted-Jensen 2025. Effects of resistance-based training and polyphenol supplementation on physical function, metabolism, and inflammation in aging individuals. GeroScience, 2025. DOI: 10.1007/s11357-025-01839-8. PMID: 40830310.
• Sun 2025. Effectiveness of multi-component exercise in individuals with type 2 diabetes: a systematic review and meta-analysis. PeerJ, 2025. DOI: 10.7717/peerj.20146. PMID: 41287857.
• Wei 2025. Exercise interventions of ≥8 weeks improve body composition, physical function, metabolism, and inflammation in older adults with stage I sarcopenic obesity: a systematic review and meta-analysis. Frontiers in Nutrition, 2025. DOI: 10.3389/fnut.2025.1575580. PMID: 40873450.
• CarrilloArango 2025. Acute systemic and energy metabolism responses to velocity‐based resistance training following an oral glucose load in individuals with excess body weight. Experimental Physiology, 2025. DOI: 10.1113/EP093162. PMID: 41379629.
• Chen 2026. Lipid biomarkers for the prediction of type 2 diabetes risk, an umbrella review and updated meta-analyses of prospective observational studies. Frontiers in Endocrinology, 2026. DOI: 10.3389/fendo.2026.1784917. PMID: 42181198.
• Jung 2024. Association between myosteatosis and impaired glucose metabolism: A deep learning whole‐body magnetic resonance imaging population phenotyping approach. Journal of Cachexia, Sarcopenia and Muscle, 2024. DOI: 10.1002/jcsm.13527. PMID: 39009381.
• Xiao 2025. Periodontal health intervention for oral health-related outcomes in older type 2 diabetes patients: a randomized controlled trial in a Chinese tertiary hospital. Scientific Reports, 2025. DOI: 10.1038/s41598-025-13434-0. PMID: 40745361.
• Lei 2023. The Effect of Sleep on Metabolism, Musculoskeletal Disease, and Mortality in the General US Population: Analysis of Results From the National Health and Nutrition Examination Survey. JMIR Public Health and Surveillance, 2023. DOI: 10.2196/46385. PMID: 37934562.
• Kemna 2025. Acute effects of lactate infusion on metabolism, AD biomarkers, and cognition: The LEAN study. Alzheimer's & Dementia, 2025. DOI: 10.1002/alz.70984. PMID: 41376120.
• Su 2022. Effects of Adult Feeding Treatments on Longevity, Fecundity, Flight Ability, and Energy Metabolism Enzymes of Grapholita molesta Moths. Insects, 2022. DOI: 10.3390/insects13080725. PMID: 36005349.
• Chen 2025. Leptin Aggravates Thoracic Aortic Dissection Through Impairment of Energy Metabolism in Nrip2 + Smooth Muscle Cells. Advanced Science, 2025. DOI: 10.1002/advs.202502027. PMID: 40667784.
• Gong 2022. Mung Bean ( Vigna radiata L.) Source Leaf Adaptation to Shading Stress Affects Not Only Photosynthetic Physiology Metabolism but Also Control of Key Gene Expression. Frontiers in Plant Science, 2022. DOI: 10.3389/fpls.2022.753264. PMID: 35185974.
• Wang 2025. Effect of betaine on growth performance, methionine metabolism, and methyl transfer in broilers aged 1 to 21 days and fed a low-methionine diet. The Journal of Poultry Science, 2025. DOI: 10.2141/jpsa.2025010. PMID: 40060329.
• Lepine 2026. Increasing plant protein sources in the diet modulates gut microbiota and tryptophan metabolism in men at cardiometabolic risk. Gut Microbes, 2026. DOI: 10.1080/19490976.2026.2677951. PMID: 42199008.
• Ma 2022. Effects of resveratrol therapy on glucose metabolism, insulin resistance, inflammation, and renal function in the elderly patients with type 2 diabetes mellitus: A randomized controlled clinical trial protocol. Medicine, 2022. DOI: 10.1097/MD.0000000000030049. PMID: 35960095.
• Ma 2024. Association of serum iron metabolism with muscle mass and frailty in older adults: A cross-sectional study of community-dwelling older adults. Medicine, 2024. DOI: 10.1097/MD.0000000000039348. PMID: 39151527.
• Wang 2025b. The effects of time-restricted eating combined with Tai Chi on glycolipid metabolism and endothelial function in postmenopausal women. Journal of the International Society of Sports Nutrition, 2025. DOI: 10.1080/15502783.2025.2581148. PMID: 41255053.
• Wang 2026. Effects of aerobic exercise on integrated cardiovascular health and energy metabolism in patients with type 2 diabetes mellitus: study protocol for a randomized controlled trial. Frontiers in Endocrinology, 2026. DOI: 10.3389/fendo.2026.1748335. PMID: 41648727.
• Liu 2022. Effects of heat stress on growth performance, carcass traits, serum metabolism, and intestinal microflora of meat rabbits. Frontiers in Microbiology, 2022. DOI: 10.3389/fmicb.2022.998095. PMID: 36519173.
• Kurhaluk 2024. Effects of a β-glucan-enriched diet on biomarkers of oxidative stress, energy metabolism and lysosomal function in muscle tissue of European grayling ( Thymallus L.). Journal of Veterinary Research, 2024. DOI: 10.2478/jvetres-2024-0064. PMID: 39776690.
• Mutoh 2025. Medium-Chain Triglyceride Dietary Supplements Reduce Glucose Metabolism of Gait-Related Skeletal Muscle in Older Adults: A Longitudinal 18 F-FDG PET/CT Analysis. Nutrients, 2025. DOI: 10.3390/nu17101707. PMID: 40431447.
• Thota 2026. Effects of Time-Restricted Eating on Ketone Metabolism and Immunoregulation in Premenopausal Women: Protocol for a Pilot, Prospective, Single-Arm Dietary Intervention Study. JMIR Research Protocols, 2026. DOI: 10.2196/81063. PMID: 41791103.
• Morvaridzadeh 2024. High-Density Lipoprotein Metabolism and Function in Cardiovascular Diseases: What about Aging and Diet Effects?. Nutrients, 2024. DOI: 10.3390/nu16050653. PMID: 38474781.
• Chen 2025b. Identification of arachidonic acid metabolism-related diagnostic markers in heart failure based on bioinformatics analysis and machine learning. Frontiers in Cardiovascular Medicine, 2025. DOI: 10.3389/fcvm.2025.1625064. PMID: 41472876.
• Vujovic 2026. From Metabolism to Longevity: Molecular Mechanisms Underlying Metformin’s Anticancer and Anti-Aging Effects. Current Issues in Molecular Biology, 2026. DOI: 10.3390/cimb48030286. PMID: 41899438.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• ADA 2024. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1). DOI: 10.2337/dc24-S006.
• WHO 2000. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. 2000. PMID: 11234459.
• Anisimov 2008. Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7(17):2769-2773. PMID: 18728386.
• Tancredi 2015. Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720-1732. DOI: 10.1056/NEJMoa1504347. PMID: 26510021.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.